Iziphumo Ezithembisayo Zonyango lwe-CD7 CAR-T Ekunyangeni i-Relapsed/Refractory Peripheral T-Cell Lymphoma kwi-ASH 2024
KwiNtlanganiso yoNyaka yama-66 ye-American Society of Hematology (ASH) ka-2024, ebibanjwe ukususela nge-7 ukuya kwi-10 kaDisemba eSan Diego, uNjingalwazi uLu Peihua weSibhedlele iLu Daopei unikezele ngovavanyo lweklinikhi lweSigaba soku-1 lwe-CD7-target Chimeric Antigen Receptor T-cell (CAR-T) therapy kunyango lwe-relapse/refractory peripheral. I-T-Cell Lymphoma (R/R PTCL). Olu luphumelelo olubalulekileyo kunyango lwe-T-cell monoancies, apho iindlela zonyango ezikhoyo bezinqongophele kwaye ngokubanzi zingasebenzi kakuhle.
I-R/R PTCL yaziwa ngokuba nefuthe elibi kwisifo sayo, ingakumbi kwizigulana eziye zafumana unyango oluhlukeneyo, kuquka ukufakelwa kweeseli ze-stem ze-allogeneic hematopoietic (allo-HSCT). Nangona kunjalo, unyango lwe-CD7 CAR-T, ngakumbi unyango lweeseli ze-NS7CAR-T oluphuhliswe liqela likaProf. Lu, lubonise iziphumo ezikhuthazayo ekunyangeni izigulana ezine-CD7-positive R/R PTCL. Kolu vavanyo, izigulana ezihlanu, ezineminyaka engama-39 ukuya kwengama-60 ubudala, ezinezigaba eziphambili ze-R/R PTCL zabhaliswa phakathi kuka-Epreli 2021 noNovemba 2023. Ezi zigulana ziye zafumana unyango oluphakathi kwemizila emithandathu yangaphambili, kuquka nelinye icala elinembali yokufakelwa kweeseli ze-stem ze-autologous.
Iziphumo bezithembisa: kwixesha eliphakathi lokulandelela leentsuku ezingama-234, ama-60% ezigulana afumene uxolelo olupheleleyo (CR), kwaye isigulane esinye sifumene uxolelo oluncinci (PR). Okubalulekileyo kukuba, unyango lubonise izinga eliphezulu lokwanda kweeseli ze-CAR-T kunye nokunyamezela kwizigulana, kunye nenqanaba eliphakathi leeseli ze-CAR-T lifikelela kwi-93.5% yokusebenza kakuhle. Okuphawulekayo kukuba, akukho ziphumo zimbi zibalulekileyo ezifana ne-neurotoxicity, kwaye i-cytokine release syndrome (CRS) yayincinci, kunye nesigulane esinye kuphela esifumana i-grade II CRS. Iprofayili yokhuseleko yayilawuleka, kungekho bungozi bukhulu bubonweyo.
Uphando lukaProf. Lu lugxininisa amandla onyango lwe-CD7 CAR-T njengotshintsho olukhulu ekunyangeni ii-T-cell monoancies, ingakumbi kwizigulana ezineendlela ezimbalwa zonyango okanye ezingenazo zonke. Ukongeza kwiziphumo ezilungileyo kwi-PTCL, iqela likaProf. Lu ngaphambili lifumene ukusebenza okugqwesileyo ekunyangeni i-T-cell acute lymphoblastic leukemia (T-ALL) kunye ne-T-cell lymphoblastic lymphoma (T-LBL), kunye nezinga lokuxolelwa elipheleleyo eliphantse libe yi-95% kwiqela lezigulana ezingama-60. Ngenxa yezi ziphumo, iqela ngoku lindisa uphando lwalo kwezinye ii-hematological monyancies ezifana ne-acute myeloid leukemia (AML), kunye nedatha yokuqala ebonisa izinga lokuxolelwa elipheleleyo elithembisayo le-70% kwizigulana ezine-CD7-positive AML.
Nangona ezi ziphumo zintle, uNjingalwazi uLu ugxininisa ukubaluleka kokudibanisa unyango lwe-CD7 CAR-T kunye ne-allo-HSCT ukuphucula iziphumo zexesha elide. Ukwahluka kwe-T-cell monicancies kufuna icebo elibanzi lonyango ukuze kwandiswe amathuba okukhululwa okuhlala ixesha elide kunye nokunyangwa okunokwenzeka. Iqela liyaqhubeka nokuphucula indlela yalo kunye nokwandisa imiqondiso yonyango lwe-CD7 CAR-T.
Umsebenzi kaNjingalwazi uLu, osele enyange izigulana ezingaphezu kwama-300 ngonyango lwe-CD7 CAR-T, umele inyathelo elikhulu phambili kunyango lwe-T-cell moldy. Ukuqhubela phambili, iqela lizimisele ukwenza uvavanyo lweklinikhi oluqhubekayo kunye nokuphucula iindlela zonyango lwe-CAR-T cell, ukuqinisekisa ukuba izigulana ezininzi ziya kuxhamla kule ndlela iphambili.
Olu vavanyo lweSigaba soku-1 oluthembisayo kwi-ASH 2024 lugxininisa amandla onyango lwe-CD7 CAR-T njengomda omtsha kwi-hematological oncology, lunika ithemba kwizigulana ezineemeko ezinganyangekiyo ngaphambili.